United States Patent 10,000,554: Claim Scrutiny and US Patent Landscape
What does US 10,000,554 claim, in enforceable terms?
US Patent 10,000,554 claims a modified laminin E8 fragment that preserves laminin E8 integrin-binding function while adding a collagen-binding moiety via fusion at an N-terminus position on one or more E8 chains.
Core claim structure (Claim 1)
- Entity: “A modified laminin”
- Building block: heterotrimeric laminin E8 fragment with integrin binding activity
- Modification: at least one of:
- α-chain N-terminus
- β-chain N-terminus
- γ-chain N-terminus
is fused with a collagen binding molecule
- Collagen-binding molecule selection (exclusive set, includes fragments/domains):
- ECM/adhesion proteins: fibronectin (collagen binding domain), von Willebrand factor
- Enzymes: collagenase; MMP-2; MMP-9
- Integrin α chains: α1, α2, α10, α11
- Immune receptors and lectin-like domains: GPVI; DDR1; DDR2; mannose receptor; PLA2 receptor; DEC205; Endol80
- Leukocyte receptors: LAIR1; LAIR2
- Binding logic implied by claim language:
- laminin E8 retains integrin binding
- collagen-binding moiety adds collagen affinity (directly, or via a collagen binding domain)
Dependent claim expansion (Claims 2-4)
- Claim 2: collagen-binding molecules are conjugated to two or more sites selected from the α/β/γ N-termini.
- Claim 3: the E8 fragment is constrained to specific chain-family ranges:
- α: one kind from α1 to α5
- β: one kind from β1 to β3
- γ: one kind from γ1 to γ3
- Claim 4: enumerates specific heterotrimer E8 combinations, including (representative list exactly as claimed):
- α5β1γ1, α3β3γ2, α1β1γ1, α1β2γ1, α2β1γ1, α2β2γ1
- α3β1γ1, α3β2γ1
- α4β1γ1, α4β2γ1
- α5β2γ1
Product and use claims (Claims 5-9)
- Claim 5: an extracellular-matrix material containing the modified laminin plus collagen and/or gelatin.
- Claim 6: a culture substrate coated with the modified laminin plus collagen and/or gelatin.
- Claim 7: a scaffold containing the modified laminin plus collagen and/or gelatin.
- Claim 8: a method for culturing mammalian cells in presence of the modified laminin plus collagen and/or gelatin.
- Claim 9: mammalian cells include ES cells, iPS cells, or somatic stem cells.
Where are the claim boundaries tight, and where are they broad?
Tight boundaries (likely to survive validity pressure)
- “Heterotrimeric laminin E8 fragment” + “integrin binding activity”
- This requires the E8 fragment be functionally defined by integrin binding, not just sequence homology.
- Fusion at chain N-terminus positions
- The claim limits modification location to α/β/γ N-termini of the E8 fragment.
- Collagen-binding molecule list is enumerated
- Claim 1 ties scope to a closed/controlled set of collagen-binding entities “selected from” the listed group.
- Dependent claims narrow chain-family ranges and enumerate specific α/β/γ combinations
- Claim 3 limits E8 constituents to α1-α5, β1-β3, γ1-γ3.
- Claim 4 narrows further to specific permutations.
Broad boundaries (likely attack surfaces)
- Functional statement “integrin binding activity”
- Can be argued as an inherent property of many laminin E8 constructs, or met by conservative variants.
- “Collagen binding molecule” includes “fragments having a collagen binding domain thereof”
- This can expand scope to many truncations, engineered variants, and domain-only constructs that still fall within the “domain” concept.
- “Conjugated to two or more sites”
- Claim 2 does not constrain linker length, chemistry, or conjugation method.
- Product/use claims do not require unique manufacturing steps
- Claims 5-9 cover materials and culture methods, which can overlap broadly with prior ECM/culture platform disclosures once the modified laminin is anticipated or obvious.
Critical claim construction risks (practical enforceability points)
1) “Fused” vs “conjugated” vs “coated”
- Claim 1 uses fused (genetically or structurally fused) at N-terminus.
- Claim 2 uses conjugated to two or more sites.
- This mix creates a potential construction dispute: whether Claim 2 requires conjugation chemistry different from the “fusion” concept of Claim 1, or whether “conjugated” is used loosely.
- In litigation, that mismatch can matter for infringement and validity mapping.
2) Collagen affinity is not directly measured in the claim
- The list of molecules is collagen-binding by nature (or because they contain collagen-binding domains), but the claim does not recite a measured binding strength.
- A competitor can attempt to argue the fusion disrupts collagen binding while still meeting the literal fusion and selection constraints.
3) Enumerated E8 combinations in Claim 4
- Claim 4 is limited to specific α/β/γ E8 assemblies.
- Competitors that use other α/β/γ E8 combinations can attempt to position outside Claim 4, while still falling under Claim 1 or Claim 2 depending on whether their E8 qualifies and whether their modifications match the N-terminus fusion concept.
How does this fit the prior art map in US practice?
Without the full patent specification and prosecution history, the landscape analysis is necessarily constrained. Under US anticipation/obviousness doctrine, what matters is whether prior art discloses:
- A laminin E8 fragment with integrin-binding function
- A collagen-binding moiety fused at α/β/γ N-termini (or functionally equivalent architecture)
- Evidence it is a heterotrimeric E8 fragment (not monomeric fragments or unrelated laminin domains)
- Any culture/scaffold/ECM usage with collagen/gelatin
In US patent-landscape terms, the patent is positioned as a domain fusion platform:
- laminin E8 provides integrin-mediated cell adhesion
- collagen-binding domains provide collagen/gelatin binding for stable ECM coatings/scaffolds
- combined with stem cell culture and biomaterial constructs
This kind of “dual-adhesion” design is a common target for obviousness arguments: if each component is known, the question becomes whether the combination and the specific fusion sites and moiety options would have been routine.
Claim-by-claim risk profile for invalidity arguments
Claim 1
Most attack-prone because it is the foundational independent claim with the widest scope:
- Broad heterotrimeric E8 fragment definition
- Closed list of collagen-binding molecules, but list includes many biologically plausible collagen binders (integrins, receptors, ECM proteins, enzymes)
- “Fragments having collagen binding domain” expands implementation space
Most defendable elements
- the specific structural requirement: fusion at N-terminus of one or more E8 chains
- maintenance of integrin binding activity
- the enumerated collagen-binding molecule set
Claim 2
Adds multi-site conjugation:
- Still broad on “two or more sites” and chemistry.
- If prior art shows multi-site conjugation on laminin fragments in general, Claim 2 faces incremental obviousness risk.
Claims 3-4
Narrow scope by chain-family restrictions and enumerated combinations:
- Generally lowers invalidity risk.
- But if prior art already uses those exact assemblies for cell adhesion, and separately uses collagen-binding fusions at equivalent positions, the combination can still be argued as obvious.
Claims 5-9
These are platform use claims:
- Obviousness risk can be high if prior art already describes coating/scaffolds for cell culture using laminin fragments plus collagen/gelatin.
- Infringement risk can remain high because materials platforms often employ broad formulations that map to “comprising … and collagen and/or gelatin.”
Practical competitive implications: where design-arounds are most plausible
Competitors can target three axes:
- Leave the E8 integrin-binding function but change architecture
- If they avoid N-terminus fusion and instead use different positions or linkers that are not “fusion” in the claim sense, they can argue non-infringement.
- Keep fusion, but swap the collagen-binding moiety
- Claim 1’s collision is the enumerated set. Using a collagen-binding protein/domain not in the list can attempt to avoid literal infringement.
- Use other laminin E8 chain combinations
- Claim 4 can be designed around by using α/β/γ pairs outside those enumerated.
- Whether that stays outside Claim 1 depends on whether their heterotrimer E8 still fits the heterotrimeric E8 fragment with integrin binding activity and whether the chain-family is limited only in dependent claims.
Patent landscape notes specific to US 10,000,554
A full, accurate US landscape requires citation to the exact patent family members, forward citations, backward citations, and the examiner’s cited references. That requires access to the patent record text and the reference list. The claim text provided does not include those elements, so a complete landscape with named US patents cannot be produced from the information here.
What can be stated from claim structure alone is that US 10,000,554 sits at the intersection of:
- laminin E8 fragment integrin-binding biomaterials
- collagen-binding domain fusions for stable coupling to collagen/gelatin
- stem cell culture coatings and scaffolds
This positioning typically draws examiners’ attention to:
- prior disclosures of laminin fragments (including E8-derived motifs) for cell adhesion
- prior disclosures of collagen-binding domains (including domains from ECM proteins and collagen-binding receptors) fused or conjugated to adhesion ligands
- known use of laminin and collagen/gelatin co-platforms for pluripotent and stem cell culture
Key Takeaways
- US 10,000,554 claims a dual-adhesion biomolecule: an integrin-binding laminin E8 heterotrimer fused with a collagen-binding molecule at α/β/γ N-termini.
- Claim 1 is the core breadth: it covers any eligible E8 heterotrimer with integrin binding plus fusion to a collagen-binding molecule from an enumerated list.
- Claims 3-4 significantly narrow to specific α/β/γ E8 compositions, creating more design-around paths through selection of heterotrimer composition.
- Claims 5-9 expand enforceable coverage into ECM materials, coatings, scaffolds, and stem-cell culture, raising obviousness overlap risk if prior art already uses laminin/collagen/gelatin platforms.
- The most meaningful validity and infringement battlegrounds are likely fusion location (N-terminus), functional integrin-binding preservation, and whether the collagen-binding moiety falls within the enumerated list including “fragments with collagen-binding domains.”
FAQs
What is the core innovation in US 10,000,554?
A modified heterotrimeric laminin E8 fragment that maintains integrin binding while adding collagen binding via fusions at the N-termini of α/β/γ E8 chains using a collagen-binding molecule selected from an enumerated set.
Which claim is the primary scope driver?
Claim 1. It defines the modified laminin architecture and the complete list of permitted collagen-binding molecules, then all downstream material and method claims depend on it.
How do dependent claims narrow infringement exposure?
Claims 3-4 restrict the laminin E8 composition to specified α/β/γ chain families and enumerated heterotrimer combinations. Claim 2 adds multi-site conjugation constraints.
What categories of collagen-binding moieties does the claim permit?
ECM/adhesion proteins and domains (fibronectin, von Willebrand factor), enzymes (collagenase, MMP-2, MMP-9), integrin α chains (α1, α2, α10, α11), and several immune/cell-surface receptors (GPVI, DDR1, DDR2, mannose receptor, PLA2 receptor, DEC205, Endol80, LAIR1, LAIR2), including collagen-binding domain fragments.
What products and applications does the patent cover beyond the molecule?
ECM materials, culture substrates, scaffolds, and methods for culturing mammalian cells, with specific coverage for ES, iPS, and somatic stem cells when the culture method uses the claimed modified laminin plus collagen and/or gelatin.
References
[1] US Patent 10,000,554, “Modified Laminin with Collagen Binding Molecule Fused to Laminin E8 Fragment,” claims text (provided in prompt).
